Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma

Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2). This cross-sectional study focuse...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Archives de pédiatrie : organe officiel de la Société française de pédiatrie 2021-05, Vol.28 (4), p.296-300
Hauptverfasser: Aydin Köker, Sultan, Kömüroğlu, Ahmet Ufuk, Köksoy, Adem Yasin, Şiraz, Ülkü Gül, Tekin, Emine, Köker, Alper
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 300
container_issue 4
container_start_page 296
container_title Archives de pédiatrie : organe officiel de la Société française de pédiatrie
container_volume 28
creator Aydin Köker, Sultan
Kömüroğlu, Ahmet Ufuk
Köksoy, Adem Yasin
Şiraz, Ülkü Gül
Tekin, Emine
Köker, Alper
description Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2). This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2±21.9 months) with IH and 45 healthy controls (mean age 21.8±15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay. Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80±4.07pg/mL vs. 5.66±4.34pg/mL, 281.10±84.12pg/mL vs. 234.19±75.38pg/mL, 1196.99±389.34pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.026, p=0.030, and p=0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69±3.94pg/mL vs. 5.66±4.34pg/mL, 289.94±83.18pg/mL vs. 234.19±75.38pg/mL, 1276.22±388.24pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.017, p=0.022, and p=0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly. Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers.
doi_str_mv 10.1016/j.arcped.2021.02.009
format Article
fullrecord <record><control><sourceid>proquest_webof</sourceid><recordid>TN_cdi_webofscience_primary_000647651500007CitationCount</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0929693X21000257</els_id><sourcerecordid>2501483579</sourcerecordid><originalsourceid>FETCH-LOGICAL-c362t-7f486277c656439465c1bc47c64808f6ea3bad5fd079f90db46d67576060842f3</originalsourceid><addsrcrecordid>eNqNkctu1DAYRi0EokPhDRDKEolJ-H2JHW-QqtEkVBqJBS3qznIcGzxK4iFOinh73GbKErHw_Xy-HCP0FkOBAfOPx0JP5mS7ggDBBZACQD5DGyy4zDlnd8_RBiRJfUnvLtCrGI8AUEFFX6ILSgUuJWUb9HV_r_tFzz6MWXBZc7i9wdvsuqlzss2-7Zt6m9VNnaU5PXapfPfhFLyd_ZiRLFV-dHqcfW-zH3Z4XB70a_TC6T7aN-f2Et3W-5vd5_zwpbneXR1yQzmZc-FYxYkQhpecUcl4aXBrWBqzdE3Hraat7krXgZBOQtcy3nFRCg4cKkYcvUTv131PU_i52DirwUdj-16PNixRkRIwq2gpZELZipopxDhZp06TH_T0W2FQDzrVUa061YNOBUQlnSn27nzC0g5p7Sn05C8BH1bgl22Di8bb0di_WBLOmeAlLlMPRKKr_6d3fn78ll1YxjlFP61Rm4Teezupc7zzkzWz6oL_91P-AFaJpDU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501483579</pqid></control><display><type>article</type><title>Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma</title><source>ScienceDirect</source><source>Web of Science - Science Citation Index Expanded - 2021&lt;img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /&gt;</source><creator>Aydin Köker, Sultan ; Kömüroğlu, Ahmet Ufuk ; Köksoy, Adem Yasin ; Şiraz, Ülkü Gül ; Tekin, Emine ; Köker, Alper</creator><creatorcontrib>Aydin Köker, Sultan ; Kömüroğlu, Ahmet Ufuk ; Köksoy, Adem Yasin ; Şiraz, Ülkü Gül ; Tekin, Emine ; Köker, Alper</creatorcontrib><description>Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2). This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2±21.9 months) with IH and 45 healthy controls (mean age 21.8±15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay. Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80±4.07pg/mL vs. 5.66±4.34pg/mL, 281.10±84.12pg/mL vs. 234.19±75.38pg/mL, 1196.99±389.34pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.026, p=0.030, and p=0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69±3.94pg/mL vs. 5.66±4.34pg/mL, 289.94±83.18pg/mL vs. 234.19±75.38pg/mL, 1276.22±388.24pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.017, p=0.022, and p=0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly. Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers.</description><identifier>ISSN: 0929-693X</identifier><identifier>EISSN: 1769-664X</identifier><identifier>DOI: 10.1016/j.arcped.2021.02.009</identifier><identifier>PMID: 33715934</identifier><language>eng</language><publisher>ISSY-LES-MOULINEAUX: Elsevier Masson SAS</publisher><subject>FGF 1 ; GLUT1 ; IGF-2 ; Infantile hemangioma ; Life Sciences &amp; Biomedicine ; Pediatrics ; Science &amp; Technology ; VEGF-A</subject><ispartof>Archives de pédiatrie : organe officiel de la Société française de pédiatrie, 2021-05, Vol.28 (4), p.296-300</ispartof><rights>2021 French Society of Pediatrics</rights><rights>Copyright © 2021 French Society of Pediatrics. Published by Elsevier Masson SAS. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>5</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000647651500007</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c362t-7f486277c656439465c1bc47c64808f6ea3bad5fd079f90db46d67576060842f3</citedby><cites>FETCH-LOGICAL-c362t-7f486277c656439465c1bc47c64808f6ea3bad5fd079f90db46d67576060842f3</cites><orcidid>0000-0003-1231-3023</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.arcped.2021.02.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,781,785,3551,27929,27930,39263,46000</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33715934$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Aydin Köker, Sultan</creatorcontrib><creatorcontrib>Kömüroğlu, Ahmet Ufuk</creatorcontrib><creatorcontrib>Köksoy, Adem Yasin</creatorcontrib><creatorcontrib>Şiraz, Ülkü Gül</creatorcontrib><creatorcontrib>Tekin, Emine</creatorcontrib><creatorcontrib>Köker, Alper</creatorcontrib><title>Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma</title><title>Archives de pédiatrie : organe officiel de la Société française de pédiatrie</title><addtitle>ARCH PEDIATRIE</addtitle><addtitle>Arch Pediatr</addtitle><description>Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2). This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2±21.9 months) with IH and 45 healthy controls (mean age 21.8±15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay. Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80±4.07pg/mL vs. 5.66±4.34pg/mL, 281.10±84.12pg/mL vs. 234.19±75.38pg/mL, 1196.99±389.34pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.026, p=0.030, and p=0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69±3.94pg/mL vs. 5.66±4.34pg/mL, 289.94±83.18pg/mL vs. 234.19±75.38pg/mL, 1276.22±388.24pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.017, p=0.022, and p=0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly. Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers.</description><subject>FGF 1</subject><subject>GLUT1</subject><subject>IGF-2</subject><subject>Infantile hemangioma</subject><subject>Life Sciences &amp; Biomedicine</subject><subject>Pediatrics</subject><subject>Science &amp; Technology</subject><subject>VEGF-A</subject><issn>0929-693X</issn><issn>1769-664X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>HGBXW</sourceid><recordid>eNqNkctu1DAYRi0EokPhDRDKEolJ-H2JHW-QqtEkVBqJBS3qznIcGzxK4iFOinh73GbKErHw_Xy-HCP0FkOBAfOPx0JP5mS7ggDBBZACQD5DGyy4zDlnd8_RBiRJfUnvLtCrGI8AUEFFX6ILSgUuJWUb9HV_r_tFzz6MWXBZc7i9wdvsuqlzss2-7Zt6m9VNnaU5PXapfPfhFLyd_ZiRLFV-dHqcfW-zH3Z4XB70a_TC6T7aN-f2Et3W-5vd5_zwpbneXR1yQzmZc-FYxYkQhpecUcl4aXBrWBqzdE3Hraat7krXgZBOQtcy3nFRCg4cKkYcvUTv131PU_i52DirwUdj-16PNixRkRIwq2gpZELZipopxDhZp06TH_T0W2FQDzrVUa061YNOBUQlnSn27nzC0g5p7Sn05C8BH1bgl22Di8bb0di_WBLOmeAlLlMPRKKr_6d3fn78ll1YxjlFP61Rm4Teezupc7zzkzWz6oL_91P-AFaJpDU</recordid><startdate>202105</startdate><enddate>202105</enddate><creator>Aydin Köker, Sultan</creator><creator>Kömüroğlu, Ahmet Ufuk</creator><creator>Köksoy, Adem Yasin</creator><creator>Şiraz, Ülkü Gül</creator><creator>Tekin, Emine</creator><creator>Köker, Alper</creator><general>Elsevier Masson SAS</general><general>Elsevier</general><scope>BLEPL</scope><scope>DTL</scope><scope>HGBXW</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1231-3023</orcidid></search><sort><creationdate>202105</creationdate><title>Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma</title><author>Aydin Köker, Sultan ; Kömüroğlu, Ahmet Ufuk ; Köksoy, Adem Yasin ; Şiraz, Ülkü Gül ; Tekin, Emine ; Köker, Alper</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c362t-7f486277c656439465c1bc47c64808f6ea3bad5fd079f90db46d67576060842f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>FGF 1</topic><topic>GLUT1</topic><topic>IGF-2</topic><topic>Infantile hemangioma</topic><topic>Life Sciences &amp; Biomedicine</topic><topic>Pediatrics</topic><topic>Science &amp; Technology</topic><topic>VEGF-A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Aydin Köker, Sultan</creatorcontrib><creatorcontrib>Kömüroğlu, Ahmet Ufuk</creatorcontrib><creatorcontrib>Köksoy, Adem Yasin</creatorcontrib><creatorcontrib>Şiraz, Ülkü Gül</creatorcontrib><creatorcontrib>Tekin, Emine</creatorcontrib><creatorcontrib>Köker, Alper</creatorcontrib><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Web of Science - Science Citation Index Expanded - 2021</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Archives de pédiatrie : organe officiel de la Société française de pédiatrie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Aydin Köker, Sultan</au><au>Kömüroğlu, Ahmet Ufuk</au><au>Köksoy, Adem Yasin</au><au>Şiraz, Ülkü Gül</au><au>Tekin, Emine</au><au>Köker, Alper</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma</atitle><jtitle>Archives de pédiatrie : organe officiel de la Société française de pédiatrie</jtitle><stitle>ARCH PEDIATRIE</stitle><addtitle>Arch Pediatr</addtitle><date>2021-05</date><risdate>2021</risdate><volume>28</volume><issue>4</issue><spage>296</spage><epage>300</epage><pages>296-300</pages><issn>0929-693X</issn><eissn>1769-664X</eissn><abstract>Infantile hemangioma (IH) is a common vascular tumor in children. It is reported that IHs are associated with immunochemical markers such as vascular endothelial growth factor (VEGF)-A, glucose transporter isoform 1 (GLUT1), and insulin-like growth factor-2 (IGF-2). This cross-sectional study focused on pediatric patients with IH. A total of 46 patients (mean age 14.2±21.9 months) with IH and 45 healthy controls (mean age 21.8±15.08 months) were enrolled. Demographic data, clinical findings, and laboratory parameters were recorded. Blood samples were collected. Serum GLUT1, IGF-2, VEGF-A, fibroblast growth factor 1 (FGF1), and angiopoietin 2 levels were assessed by enzyme-linked immunosorbent assay. Serum GLUT1, IGF-2, and VEGF-A levels were significantly higher in patients with IH than in healthy controls (8.80±4.07pg/mL vs. 5.66±4.34pg/mL, 281.10±84.12pg/mL vs. 234.19±75.38pg/mL, 1196.99±389.34pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.026, p=0.030, and p=0.036). Serum GLUT1, IGF-2, and VEGF-A levels in patients with complicated hemangioma were significantly higher than in healthy controls (9.69±3.94pg/mL vs. 5.66±4.34pg/mL, 289.94±83.18pg/mL vs. 234.19±75.38pg/mL, 1276.22±388.24pg/mL vs. 996.99±349.16pg/mL, respectively, p=0.017, p=0.022, and p=0.011). Serum GLUT1, IGF-2, and VEGF-A levels in patients with hemangioma receiving propranolol treatment were significantly higher than in healthy controls. Serum FGF1 levels were higher in patients with IH, complicated hemangioma, and hemangioma receiving propranolol treatment than in healthy controls but the difference was not statistically significantly. Serum GLUT1, IGF-2, and VEGF-A levels were positively correlated with disease severity in patients with hemangioma, for example, in complicated hemangioma and hemangioma requiring propranolol treatment. However, further research on larger and different age subgroups is warranted to assess these markers.</abstract><cop>ISSY-LES-MOULINEAUX</cop><pub>Elsevier Masson SAS</pub><pmid>33715934</pmid><doi>10.1016/j.arcped.2021.02.009</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0003-1231-3023</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0929-693X
ispartof Archives de pédiatrie : organe officiel de la Société française de pédiatrie, 2021-05, Vol.28 (4), p.296-300
issn 0929-693X
1769-664X
language eng
recordid cdi_webofscience_primary_000647651500007CitationCount
source ScienceDirect; Web of Science - Science Citation Index Expanded - 2021<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />
subjects FGF 1
GLUT1
IGF-2
Infantile hemangioma
Life Sciences & Biomedicine
Pediatrics
Science & Technology
VEGF-A
title Evaluation of GLUT1, IGF-2, VEGF, FGF 1, and angiopoietin 2 in infantile hemangioma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T18%3A12%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_webof&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20GLUT1,%20IGF-2,%20VEGF,%20FGF%201,%20and%20angiopoietin%202%20in%20infantile%20hemangioma&rft.jtitle=Archives%20de%20p%C3%A9diatrie%20:%20organe%20officiel%20de%20la%20Soci%C3%A9t%C3%A9%20fran%C3%A7aise%20de%20p%C3%A9diatrie&rft.au=Aydin%20K%C3%B6ker,%20Sultan&rft.date=2021-05&rft.volume=28&rft.issue=4&rft.spage=296&rft.epage=300&rft.pages=296-300&rft.issn=0929-693X&rft.eissn=1769-664X&rft_id=info:doi/10.1016/j.arcped.2021.02.009&rft_dat=%3Cproquest_webof%3E2501483579%3C/proquest_webof%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501483579&rft_id=info:pmid/33715934&rft_els_id=S0929693X21000257&rfr_iscdi=true